How effective is cabozantinib? Treatment data for different cancer types

Cabozantinib is an oral multi-target tyrosine kinase inhibitor that mainly interferes with tumor angiogenesis, metastasis and tumor cell proliferation by inhibiting various receptor tyrosine kinases such as VEGFR, MET and Axl. It has been approved to treat several types of cancer, including renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, and others. The therapeutic effects of cabozantinib vary by cancer type, but overall, it has shown positive results in the treatment of a variety of cancers.

In the treatment of renal cell carcinoma (RCC), cabozantinib is widely used. Clinical studies have shown that cabozantinib has significant anti-tumor effects in advanced renal cell carcinoma, especially in patients who have received other treatments, such as anti-PD-1 or VEGF inhibitors. Studies have shown that cabozantinib can significantly improve progression-free survival (PFS) and overall survival (OS). For example, cabozantinib shows stronger efficacy when used in combination with immunotherapy, further improving patient survival and quality of life.

In the treatment of hepatocellular carcinoma (HCC), cabozantinib has also shown good efficacy. It is used as first-line or second-line treatment of liver cancer, especially in patients who have progressed after prior treatment with sorafenib. Cabozantinib helps reduce the blood supply of tumors and prevent the spread of tumors by inhibiting targets such as VEGFR and MET. The study results show that cabozantinib can significantly extend progression-free survival and improve overall survival in patients with hepatocellular carcinoma, especially in patients who have failed other treatments.

For patients with thyroid cancer, especially those with advanced and unresectable differentiated thyroid cancer (DTC), cabozantinib also shows good therapeutic effects. Although cabozantinib has limited use in the treatment of thyroid cancer, in some special cases, especially when traditional treatments are ineffective, cabozantinib has shown its potential to slow tumor progression by inhibiting multiple growth factor pathways. Clinical data show that cabozantinib can delay disease progression and improve survival of patients with advanced thyroid cancer.

Reference:https://en.wikipedia.org/wiki/Cabozantinib